Search Results for: covid-19
Articles
Catalent to be Added to S&P 500 Index September 15, 2020
Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell...RedHill Biopharma’s Opaganib Demonstrates Complete Inhibition of SARS-CoV-2 September 9, 2020
RedHill Biopharma Ltd. recently announced that opaganib demonstrated potent inhibition of SARS-CoV-2, the virus that causes COVID-19, achieving complete blockage of viral...Liminal BioSciences Announces Resubmission of Biologics License Application September 9, 2020
Liminal BioSciences Inc. recently announced the company, through its US subsidiary Prometic Biotherapeutics Inc., has filed a resubmission of the...Cymerus MSCs Demonstrate Efficacy in Preclinical Lung Disease Study September 9, 2020
Cynata Therapeutics Limited recently announced positive efficacy data from a study of its induced pluripotent stem cell (iPSC)-derived Cymerus mesenchymal...Spero Therapeutics Announces Positive Topline Results From its Phase 3 ADAPT-PO Clinical Trial September 9, 2020
Spero Therapeutics, Inc. recently announced positive topline results from ADAPT-PO, the pivotal Phase 3 clinical trial evaluating Spero’s oral antibiotic...Catalent Biologics Invests $50 Million to Add Third High-Speed Vial Line September 2, 2020
Catalent recently announced it is investing $50 million to install an additional high-speed vial filling line at its Bloomington, IN,...Micron Biomedical Progresses With Clinical Evaluation of its Technology for Measles-Rubella Vaccination September 2, 2020
Micron Biomedical, Inc. (Micron) recently received a second tranche of funding ($2.6 million) to continue clinical development of its microneedle-based...EXECUTIVE INTERVIEW - AMO Pharma: Identifying & Developing Cancer Pathway Therapeutic Candidates for Use in New Neurological Indications August 31, 2020
Michael Snape, PhD, AMO Pharma’s Chief Scientific Officer, discusses the company’s research focus and efforts to understand and target the mechanism of action of CNS disorders associated with developmental delay with the potential to target neurogenetic disorders at their root cause.
2020 Analytical Testing in Drug Development e-Book: A Critical Role in End-to-End Drug Development August 24, 2020
This second annual Drug Development & Delivery Analytical Testing eBook shines a light on analytical outsourcing providers that are optimizing testing solutions to ensure more robust results, speed time to market, and characterize methods earlier in development.
ANA Therapeutics & Quotient Sciences Announce Manufacturing Partnership August 20, 2020
ANA Therapeutics, a Silicon Valley-based biotech start-up, and Quotient Sciences, a leading provider of innovative drug development and manufacturing solutions, recently announced a partnership to support the….
EyePoint Pharmaceuticals Receives $9.5 Million From Ocumension Therapeutics Under Expanded License Agreements August 20, 2020
EyePoint Pharmaceuticals, Inc. and Ocumension Therapeutics recently announced the expansion of their exclusive license agreements for the development and commercialization of….
Humanetics Corporation & Pharmaceutics International, Inc. Announce Partnership August 20, 2020
Humanetics Corporation and Pharmaceutics International, Inc. (Pii) will work together to support a clinical trial of BIO 300 in COVID-19 patients…..
Organicell Provides Phase 1/2 Clinical Trial Update August 19, 2020
Organicell Regenerative Medicine, Inc. recently announced it has partnered with Alternative Research Associates, LLC and Larkin Hospital in Miami, FL,...TFF Pharmaceuticals Enters into Worldwide Licensing Agreement With UNION Therapeutics August 19, 2020
TFF Pharmaceuticals, Inc. recently announced it has entered into a worldwide exclusive licensing agreement with UNION therapeutics A/S (UNION) for...Immunic, Inc. Reports Positive Top-line Data From Phase 2 EMPhASIS Trial August 7, 2020
Immunic, Inc. recently announced positive top-line data from its phase 2 EMPhASIS trial of lead asset, IMU-838, the company’s selective...Corbus Pharmaceuticals Completes Enrollment in Phase 3 Study August 7, 2020
Corbus Pharmaceuticals Holdings, Inc. recently announced the completion of subject enrollment in DETERMINE, a Phase 3 study assessing the efficacy...Don’t Miss RNA Medicine in a Pandemic Symposium on July 23! July 8, 2020
Join us as we are hosting an RNA Symposium bringing together leading experts in RNA medicine, delivery, technology development, and solutions for manufacturing to present and discuss…
Timber Pharmaceuticals Announces All CONTROL Study Sites Open & Enrolling Patients With Moderate-to-Severe Congenital Ichthyosis July 1, 2020
Timber Pharmaceuticals, Inc. recently announced that all 11 sites across the US and Australia participating in the Phase 2b CONTROL study evaluating TMB-001 (topical isotretinoin) are now….
2020 Respiratory Drug Development eBook – Inhaled Medications for Treating Unconventional Respiratory Diseases June 30, 2020
This second annual Drug Development & Delivery Respiratory eBook focuses on a few companies that are taking inhalation devices to a new level in drug delivery.
Ajinomoto Bio-Pharma Services Introduces AJILITY Fast-Track Platform for Drug Product Manufacturing June 30, 2020
Ajinomoto Bio-Pharma Services recently announce the launch of AJILITY, a flexible and agile drug product manufacturing platform, designed to advance….
